SOX2 and ovarian carcinoma: In ovarian cancer patients receiving taxanes, expression of SOX-2 was shown to be correlated with chemotherapy resistance and a shorter PFS whereas patients receiving non-taxane based chemotherapy showed no significant response influence [31].